4 withdrawn, 2 completed, 2 unknown, 1 not yet recruiting. 5 Phase 2, 4 Phase 1, 2 Not applicable, 1 Early Phase 1, 1 Phase 3.
Follow Toxic Epidermal Necrolysis: new trials by email Literature Review of Toxic Epidermal Necrolysis trials Research Report on Toxic Epidermal Necrolysis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal Necrolysis Site specific standard of care comparison - Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis | Withdrawn | Massachusetts General Hospital | 2030-01-01 | 2026-01-16 | ||
| New Therapeutic Target for Toxic Epidermal Necrolysis (TEN) Using Anti-CD38+ Monoclonal Antibodies. DARATUMUMAB (DARZALEX®) - Toxic Epidermal Necrolysis, Immunotherapy | Phase 1 / Phase 2 | Not yet recruiting | Hospices Civils de Lyon | 9 | 2025-10-29 | 2025-08-07 |
| LYell SYndrome MEsenchymal Stromal Cells Treatment Adipose derived stromal cells intravenously injected - Epidermal Necrolysis, Lyell Syndrome | Phase 1 / Phase 2 | Recruiting | Assistance Publique - Hôpitaux de Paris | 15 | 2024-04-15 | 2025-08-01 |
| Evaluation of the Efficacy and Safety of Methylprednisolone Combined With the JAK Inhibitors in the Treatment of Toxic Epidermal Necrolysis Abrocitinib, Tofacitinib - Toxic Epidermal Necrolysis | Early Phase 1 | Unknown | Peng Zhang | 30 | 2023-07-05 | 2023-11-28 |
| Study To Evaluate The Efficacy Of Tofacitinib In Patients With SJS/TEN Tofacitinib - Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis | Not applicable | Completed | Chang Gung Memorial Hospital | 20 | 2022-08-01 | 2025-09-16 |
| Topical Clobetasol for the Treatment of Toxic Epidermal Necrolysis Clobetasol 0.05% ointment, Placebo - Toxic Epidermal Necrolysis | Phase 1 / Phase 2 | Withdrawn | University of California, Davis | 2016-11-01 | 2019-08-09 | |
| Evaluating the Effect of Isotretinoin in Regulatory T-cell Function in Adverse Cutaneous Drug Eruptions (ACDEs): A Pilot Study Isotretinoin, Placebo - Toxic Epidermal Necrolysis | Not applicable | Withdrawn | Massachusetts General Hospital | 2016-11-01 | 2023-06-07 | |
| Severe Cutaneous Adverse Reactions in Thailand Steven-Johnson Syndrome, Toxic Epidermal Necrolysis | Unknown | Chulalongkorn University | 200 | 2014-01-01 | 2019-02-18 | |
| Phase III Clinical Trial of NPB-01 in Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids. Intravenous immunoglobulin - Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis | Phase 3 | Completed | Nihon Pharmaceutical Co., Ltd | 10 | 2012-10-01 | 2014-07-02 |
| Study to Evaluate the Use of Palifermin to Treat Toxic Epidermal Necrolysis Palifermin - Toxic Epidermal Necrolysis, Stevens-Johnson Syndrome | Phase 1 / Phase 2 | Terminated | Brett King | 1 | 2010-10-01 | 2016-11-30 |
| Study of a Potential New Treatment for Patients With Toxic Epidermal Necrolysis (TEN) Remicaide (infliximab) - Toxic Epidermal Necrolysis | Phase 2 | Withdrawn | Loyola University | 2006-07-01 | 2013-04-26 |
Stevens-Johnson Syndrome (11) · Drug-Related Side Effects and Adverse Reactions (2) · Acute Generalized Exanthematous Pustulosis (1) · Drug Hypersensitivity (1) · Drug Hypersensitivity Syndrome (1)
Chemically-Induced Disorders (11) · Dermatitis (11) · Drug Eruptions (11) · Erythema (11) · Erythema Multiforme (11) · Hypersensitivity (11) · Hypersensitivity, Delayed (11) · Immune System Diseases (11) · Mouth Diseases (11) · Skin Diseases (11) · Skin Diseases, Vesiculobullous (11) · Skin and Connective Tissue Diseases (11) · Stomatitis (11) · Stomatognathic Diseases (11) · Drug Hypersensitivity (10)
tofacitinib (2) · Clobetasol (1) · Fibroblast Growth Factor 7 (1) · Immunoglobulins, Intravenous (1) · Infliximab (1) · Isotretinoin (1) · Methylprednisolone Hemisuccinate (1) · Ointments (1) · abrocitinib (1) · daratumumab (1)
Massachusetts General Hospital (2) · Assistance Publique - Hôpitaux de Paris (1) · Brett King (1) · Chang Gung Memorial Hospital (1) · Chulalongkorn University (1) · Hospices Civils de Lyon (1) · Loyola University (1) · Nihon Pharmaceutical Co., Ltd (1) · Peng Zhang (1) · University of California, Davis (1)
United States (3) · France (2) · China (1) · Japan (1) · Taiwan (1) · Thailand (1)
Arturo Saavedra, MD, PhD (1) · Chun Bing Chen (1) · Emanual Maverakis, MD (1) · Jettanong Klaewsongkram, MD (1) · Richard Gamelli, MD (1) · Saskia Oro, PhD (1)
PMID 26297574, PMID 27106261, PMID 28476287, PMID 29478292, PMID 29800753, PMID 30346532, PMID 34734507, PMID 37678574